Taisho Pharmaceutical Holdings Co., Ltd.
4581
주식 순위
#3722
Taisho Pharmaceutical Holdings Co., Ltd. is a global healthcare enterprise... Taisho Pharmaceutical Holdings Co., Ltd. is a global healthcare enterprise involved in the comprehensive research, development, production, marketing, and distribution of both non-prescription (OTC) and ethical pharmaceutical products, serving markets in Japan and worldwide. The company's operations are divided into two principal divisions: the Self-Medication Operation Group and the Prescription Pharmaceutical Operation Group. The Self-Medication Group provides a diverse portfolio of consumer health products, including over-the-counter medicines, quasi-pharmaceuticals, food products, and general medical and hygiene items. Prominent brands within this segment include the Lipovitan energy drink series, Pabron cold and sinus remedies, RiUP hair re-growth solutions, Taisho Kampo gastrointestinal treatments, Colac laxatives, Naron and other pain relievers for fever, Preser hemorrhoid treatments, Hapacol, Efferalgan, Dafalgan, and Tempra for antipyretic-analgesic relief, Counterpain topical anti-inflammatory products, Vitacilina dermatological treatments, and VICKS cough suppressant throat lozenges and medicated drops. This division also encompasses real estate leasing, facility management, and hotel operations. Conversely, the Prescription Pharmaceutical Group specializes in ethical drugs such as Edirol, an active vitamin D3 agent for osteoporosis; Clarith, a macrolide antibiotic; Palux, a peripheral vasodilator; Bonviva, a bisphosphonate for osteoporosis; Lusefi, an agent for type 2 diabetes mellitus; and LOQOA, a transdermal anti-inflammatory analgesic. This segment is also engaged in ongoing drug development, primarily focusing on therapeutic areas like central nervous system disorders, infectious diseases, metabolic conditions, and orthopedic ailments. Additionally, Taisho Pharmaceutical Holdings supplies raw materials for pharmaceutical and quasi-drug manufacturing, alongside offering health foods and skincare products. The company was established in Tokyo, Japan, in 1912, where its headquarters remain.
주가
$54.31
마지막 동기화: 2024-04-08
시가총액
$4.45B
변동 (1일)
-4.14%
변동 (1년)
0.00%
국가
JP
거래 Taisho Pharmaceutical Holdings Co., Ltd. (4581)
카테고리
Healthcare
Taisho Pharmaceutical Holdings Co., Ltd. (4581)의 발행 주식 수
October 2026 기준 발행 주식 수: 0
Taisho Pharmaceutical Holdings Co., Ltd.의 최신 재무 보고서와 주가에 따르면 현재 발행 주식 수는 0입니다. October 2026 말 기준 회사는 0주를 발행했습니다. 발행 주식 수는 일반적으로 주식 분할이나 자사주 매입에 의해 영향을 받습니다.
Taisho Pharmaceutical Holdings Co., Ltd. (4581)의 발행 주식 수 기록 (2006 ~ 2026)
매년 말 기준 발행 주식 수
| 연도 | 발행 주식 수 | 변화 |
|---|---|---|
| 2023 | 81.98M | 0.66% |
| 2022 | 81.44M | 2.04% |
| 2021 | 79.82M | 0.00% |
| 2020 | 79.82M | 0.00% |
| 2019 | 79.82M | -0.09% |
| 2018 | 79.89M | -0.02% |
| 2017 | 79.91M | -1.24% |
| 2016 | 80.91M | -0.19% |
| 2015 | 81.07M | -0.02% |
| 2014 | 81.09M | 0.21% |
| 2013 | 80.92M | -1.60% |
| 2012 | 82.23M | -1.88% |
| 2011 | 83.81M | -2.54% |
| 2010 | 85.99M | -2.41% |
| 2009 | 88.12M | -1.32% |
| 2008 | 89.29M | -2.51% |
| 2007 | 91.60M | -0.95% |
| 2006 | 92.47M | 0.00% |
유사 기업 또는 경쟁사의 발행 주식 수
| 회사 | 발행 주식 수 | 차이 | 국가 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 2.40B | - |
IN
|
